FDA has issued a guidance intended to help expand the availability of media used to transport certain clinical specimens for testing during the covid-19 public health emergency. The guidance is titled “Enforcement Policy for Viral Transport Media During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency: Guidance for Commercial Manufacturers, Clinical Laboratories, and Food and Drug Administration Staff.” FDA is issuing this guidance to help facilitate the availability of devices for use in transporting certain clinical specimens, including transport media that can be used to transport certain clinical specimens for use with molecular reverse transcriptase-polymerase chain reaction (RT-PCR) SARS-CoV-2 assays or antigen-detection diagnostic SARS-CoV-2 assays for the duration of the covid-19 public health emergency. The FDA also posted answers to frequently asked questions relating to the development. Read more from FDA.